Nuclear Medicine Communications

Papers
(The H4-Index of Nuclear Medicine Communications is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
PET/computed tomography radiomics combined with clinical features in predicting sarcopenia and prognosis of diffuse large B-cell lymphoma42
Simulated daily readout for maintaining nuclear medicine education in residency training amidst declining case volume: evidence from the COVID-19 pandemic28
[18F]-PSMA-1007 PET imaging optimization and inter-rater reliability – a comparison of three different reconstructions read by four radiologists22
Is a strict restricted-iodine diet necessary for preparation of radioactive iodine therapy?20
Comparison of the role of 18F-fluorodeoxyglucose PET/computed tomography and 68Ga-labeled FAP inhibitor-04 PET/CT in patients with malignant mesothelioma19
Diagnostic value of single-photon emission computed tomography-CT foot and ankle studies18
Prognostic value of lung shunt fraction in hepatocellular carcinoma and unresectable liver dominant metastatic colorectal cancer undergoing transarterial radioembolisation18
Associations between brown adipose tissue activity, serum lipid profiles, and cardiovascular events: insights from 18F-fluorodeoxyglucose PET/computed tomography analysis15
Outcomes of I-131 therapy in pediatric and adolescent differentiated thyroid cancer: a long-term follow-up of a single-center Indian cohort14
Comparison of 68Ga-FAPI-04 and fluorine-18-fluorodeoxyglucose PET/computed tomography in the detection of ovarian malignancies14
Semiquantitative analysis of 18F-aluminum fluoride fibroblast activation protein inhibitor 42 PET/computed tomography in primary liver cancer and factors influencing imaging positivity rates13
Relation of whole-body metabolic tumor volume and total lesion glycolysis on fluorodeoxyglucose PET/computed tomography with clinical and laboratory parameters in newly diagnosed multiple myeloma13
Validation of the Prostate Imaging for Recurrence Reporting (PI-RR) System using 68Ga prostate-specific membrane antigen-11 (HBED-CC) PET/MRI in biochemical recurrence of prostate cancer: a pilot stud12
0.050963878631592